The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes

Pregnant women aged 18-49 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.

Start Date01 Sep 2024

Sponsor / Collaborator

Jaeb Center For Health Research Foundation, Inc.

[+1]

NCT05904743

/ CompletedPhase 4

INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.

Start Date07 Jul 2023

Sponsor / Collaborator

MannKind Corp.

[+1]

NCT05243628

/ CompletedPhase 4

ABC [Afrezza With Basal Combination]: A Phase 4 Study of Mealtime Control With Afrezza in Adult Subjects With Type 1 Diabetes Mellitus in Combination With an Automated Insulin Pump or Insulin Degludec

A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes

Start Date31 Mar 2022

Sponsor / Collaborator

MannKind Corp.

100 Clinical Results associated with Insulin Recombinant Human(MannKind)

100 Translational Medicine associated with Insulin Recombinant Human(MannKind)

100 Patents (Medical) associated with Insulin Recombinant Human(MannKind)

Literatures (Medical) associated with Insulin Recombinant Human(MannKind)

01 Jun 2024·Current diabetes reports

Prandial Insulins: A Person-Centered Choice

Review

Author: Shaikh, Shehla ; Attri, Bhawna ; Kalra, Sanjay ; Nagendra, Lakshmi ; Bhattacharya, Saptarshi ; Shetty, Sahana ; Dutta, Deep

PURPOSE OF REVIEW:

Postprandial hyperglycemia, or elevated blood glucose after meals, is associated with the development and progression of various diabetes-related complications. Prandial insulins are designed to replicate the natural insulin release after meals and are highly effective in managing post-meal glucose spikes. Currently, different types of prandial insulins are available such as human regular insulin, rapid-acting analogs, ultra-rapid-acting analogs, and inhaled insulins. Knowledge about diverse landscape of prandial insulin will optimize glycemic management.

RECENT FINDINGS:

Human regular insulin, identical to insulin produced by the human pancreas, has a slower onset and extended duration, potentially leading to post-meal hyperglycemia and later hypoglycemia. In contrast, rapid-acting analogs, such as lispro, aspart, and glulisine, are new insulin types with amino acid modifications that enhance their subcutaneous absorption, resulting in a faster onset and shorter action duration. Ultra-rapid analogs, like faster aspart and ultra-rapid lispro, offer even shorter onset of action, providing better meal-time flexibility. The Technosphere insulin offers an inhaled route for prandial insulin delivery. The prandial insulins can be incorporated into basal-bolus, basal plus, or prandial-only regimens or delivered through insulin pumps. Human regular insulin, aspart, lispro, and faster aspart are recommended for management of hyperglycemia during pregnancy. Ongoing research is focused on refining prandial insulin replacement and exploring newer delivery methods. The article provides a comprehensive overview of various prandial insulin options and their clinical applications in the management of diabetes.

01 Mar 2023·Diabetes therapy : research, treatment and education of diabetes and related disorders

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes

Article

Author: Kaiserman, Kevin B ; Haller, Michael J ; Jones, Marisa C ; Bhavsar, Sunil

INTRODUCTION:

Technosphere insulin (TI) is an inhaled dry powder ultra-rapid-acting insulin. This report describes the results of the first study of TI in children with type 1 diabetes (T1D).

METHODS:

Pharmacokinetics (PK) of TI and the effect of TI on circulating glucose concentrations were evaluated in a single-arm study that enrolled children ages 8-17 years with T1D for more than 1 year, on a stable multiple daily insulin injection (MDI) regimen, and meeting pre-defined pulmonary function testing criteria (at least 70% predicted). To assess PK, subjects received an individualized single preprandial dose of TI (4-12 U, in 4-U increments) via oral inhalation, based on their usual meal-time subcutaneously injected rapid-acting insulin dose and meal content. Serum insulin and blood glucose were measured at - 30 to 250 min relative to dosing.

RESULTS:

Twenty-seven children with T1D participated in this single-dose PK study. Mean subject age was 13.3 years (59% female; 81.5% White). Mean serum insulin C_max (maximum concentration) was 77.3, 119.15, and 207.7 µU/mL for doses of 4, 8, and 12 U, respectively. T_max occurred at 10.5, 13.9, and 14.6 min post-dose for 4, 8, and 12 U. Glucose lowering 30-60 min post-dose was consistent with the PK profile.

CONCLUSION:

Serum insulin rapidly increased post-dose and returned to baseline by 120 min. The data suggests the PK of TI in youth with T1D ages 8-17 years was similar to that seen in previous adult studies.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT02527265.

01 Jan 2023·Annals of biomedical engineering

Transforming Evidence Generation for Drug Label Changes: A Case Study

Article

Author: Desborough, Lane ; Ulloa, Johanna ; Kaiserman, Kevin ; Jaffe, Karen ; Hanna, Joseph

Computer Modeling and Simulation (CM&S) provides the opportunity to drastically reduce clinical trial patient burden and advance regulatory decision making. At the suggestion of the US Food and Drug Administration (FDA), MannKind Corporation and Nudge BG submitted an application to the FDA Model-Informed Drug Development (MIDD) pilot program to support a label change for the initial dose of Afrezza® (insulin human), a novel inhalable insulin with a rapid pharmacokinetic and pharmacodynamic profile. The MIDD pilot program demonstrates the FDA's commitment to advancing regulatory science through the adoption of evidence generated by CM&S. A simulation framework was developed based on empirical data. It was used to generate evidence to support the label change. Briefing packages and presentations were prepared for two meetings with the FDA, over a period of four months. The model was thoroughly characterized, determined to be low risk for the question of interest, and submitted along with additional clinical evidence for validation. The FDA found the simulation framework to be helpful in providing insights into the question of interest and provides reasonable glycemic outcome predictions. At the conclusion of the MIDD paired meetings, FDA personnel from the Center for Drug Evaluation and Research review team accepted the simulation and requested additional, traditional clinical evidence to support the proposed label change. In the post-meeting comments, the FDA invited MannKind to submit a proposal for a data package including the CM&S evidence in a Type C meeting for further discussion on the label change. This MIDD pilot experience suggests that CM&S is a credible method for evidence generation. Collaboration between sponsor organizations as well as all stakeholders in the FDA, including proponents of CM&S, can further support regulatory decision-making. The learnings from early participants will allow the program to reach its full potential and thereby ultimately benefit patients, sponsors, and FDA.

News (Medical) associated with Insulin Recombinant Human(MannKind)

17 Dec 2024

·www.globenewswire.com

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression Dec. 16, 2024 -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) in 1H 2025 to discuss the data and filing timeline. The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. The primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. A 26-week extension phase in which all remaining MDI patients switched to Afrezza is still ongoing. Results were as follows: * mITT analysis excludes one outlier from the primary ITT endpoint who failed to adhere to the study protocol An analysis of the full intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, no difference in lung function parameters were seen between the treatment groups. The Afrezza-treated patients had a mean FEV1 of 2.901 liters (99.6% of predicted) at baseline and 2.934 liters (96.6% of predicted) at 26 weeks. MDI-treated patients had corresponding mean FEV1 values of 2.948 liters (102.3% of predicted) and 2.957 liters (98% of predicted), respectively. Additional safety findings, including for hypoglycemia, did not show any significant concerns or differences between the treatment groups. “The overall efficacy and safety outcomes seen in the first 26 weeks are encouraging. This represents a monumental step in our more than 25-year history of pioneering the development of inhaled insulin and working to bring this new treatment option to children and adolescents over the past seven years,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. “It was exciting to partner with MannKind and help lead this study to potentially expand the use of inhaled insulin, which is currently used successfully by many adults with diabetes, to a population that hasn’t had a treatment option other than injectable insulin in the history of their care,” said Dr. Roy W. Beck, founder of the Jaeb Center for Health Research who provided oversight for INHALE-1. “The six-month results are clinically meaningful and show Afrezza as a potential future treatment option for a growing pediatric population living with type 1 and type 2 diabetes.” Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

16 Dec 2024

·www.drugs.com

Technosphere Insulin + Insulin Degludec Noninferior to Usual Care in T1DM

MONDAY, Dec. 16, 2024 -- For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, according to a study published online Dec. 6 in Diabetes Care . Irl B. Hirsch, M.D., from the University of Washington in Seattle, and colleagues examined a regimen of TI plus insulin degludec in adults with type 1 diabetes who were mainly using an automated insulin delivery (AID) system or multiple daily insulin injections (MDI) with continuous glucose monitoring prestudy. Adults with type 1 diabetes at 19 sites were randomly assigned to TI plus insulin degludec or usual care with continuation of the prestudy insulin delivery method for 17 weeks (62 and 61 patients, respectively). The researchers found that mean hemoglobin A1c was 7.57 ± 0.97 and 7.62 ± 1.06 percent at baseline and 17 weeks, respectively, in the TI group, and 7.59 ± 0.80 and 7.54 ± 0.77 percent, respectively, in the usual care group (P for noninferiority, 0.01). From baseline to 17 weeks, improvement in hemoglobin A1c by >0.5 percent was seen in 12 patients (21 percent) in the TI group and in three patients (5 percent) in the usual care group; hemoglobin A1c worsened by >0.5 percent in 15 (26 percent) and in two (3 percent) of the participants in the TI and usual care groups, respectively. A brief cough was the most common TI side effect; due to side effects, eight participants discontinued TI. "While the study results support consideration of TI as a viable option for patients with type 1 diabetes, patient selection with respect to prescribing TI is important," the authors write. Several authors disclosed ties to pharmaceutical companies, including MannKind, which funded the study. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultAHA

16 Dec 2024

·investors.mannkindcorp.com

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) in 1H 2025 to discuss the data and filing timeline. The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin. The primary endpoint was a non-inferior change in HbA1c levels after 26 weeks. A 26-week extension phase in which all remaining MDI patients switched to Afrezza is still ongoing. Results were as follows: * mITT analysis excludes one outlier from the primary ITT endpoint who failed to adhere to the study protocol An analysis of the full intent-to-treat population (ITT) found that the between-group difference in mean HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, no difference in lung function parameters were seen between the treatment groups. The Afrezza-treated patients had a mean FEV1 of 2.901 liters (99.6% of predicted) at baseline and 2.934 liters (96.6% of predicted) at 26 weeks. MDI-treated patients had corresponding mean FEV1 values of 2.948 liters (102.3% of predicted) and 2.957 liters (98% of predicted), respectively. Additional safety findings, including for hypoglycemia, did not show any significant concerns or differences between the treatment groups. “The overall efficacy and safety outcomes seen in the first 26 weeks are encouraging. This represents a monumental step in our more than 25-year history of pioneering the development of inhaled insulin and working to bring this new treatment option to children and adolescents over the past seven years,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. “It was exciting to partner with MannKind and help lead this study to potentially expand the use of inhaled insulin, which is currently used successfully by many adults with diabetes, to a population that hasn’t had a treatment option other than injectable insulin in the history of their care,” said Dr. Roy W. Beck, founder of the Jaeb Center for Health Research who provided oversight for INHALE-1. “The six-month results are clinically meaningful and show Afrezza as a potential future treatment option for a growing pediatric population living with type 1 and type 2 diabetes.” Conference Call MannKind will host a live audio webcast beginning at 8:30 a.m. Eastern Time on Monday, December 16, 2024, to share results and discuss the company’s diabetes program progression. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD and Dr. Kaiserman. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About Afrezza Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking. Important Safety Information WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in Afrezza-treated patients with asthma and COPD Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD Before initiating Afrezza, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients. Most common adverse reactions are hypoglycemia, cough, and throat pain or irritation. Please see additional Important Safety Information, Full Prescribing Information, including BOXED WARNING, available on Afrezza.com/safety. About MannKind MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram. Forward-Looking Statements This press release contains forward-looking statements about a planned meeting with the FDA, a potential sNDA submission and the potential expanded use of Afrezza that involves risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the review by the FDA may subject us to unanticipated delays or prevent us from obtaining the expanded indication as well as other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. AFREZZA and MANNKIND are registered trademarks of MannKind Corporation. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/12f4dac8-7936-41b3-a2ad-7eef85fe3712 Source: MannKind

Clinical ResultPhase 3

100 Deals associated with Insulin Recombinant Human(MannKind)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Insulin Recombinant Human(MannKind)	A10AF01 A10AD01 A10AC01	DB00030

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	US	MannKind Corp.	27 Jun 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes, Gestational	Phase 3	US	MannKind Corp.	01 Sep 2024
Glucose Intolerance	Phase 3	US	MannKind Corp.	01 Sep 2024
Moderate chronic obstructive pulmonary disease	Phase 3	US	MannKind Corp.	01 Mar 2009
Moderate chronic obstructive pulmonary disease	Phase 3	RU	MannKind Corp.	01 Mar 2009
Moderate chronic obstructive pulmonary disease	Phase 3	UA	MannKind Corp.	01 Mar 2009
Asthma	Phase 3	US	MannKind Corp.	01 Jun 2006
Asthma	Phase 3	AR	MannKind Corp.	01 Jun 2006
Asthma	Phase 3	BR	MannKind Corp.	01 Jun 2006
Asthma	Phase 3	CA	MannKind Corp.	01 Jun 2006
Asthma	Phase 3	CZ	MannKind Corp.	01 Jun 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04974528 (INHALE-1, Company_Website) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Diabetes Mellitus, Type 1	230	Afrezza	xnysdloqlz(eevtdoxlso) = fqvjoqanni ctsubxhpvj (gwdfoaffsw )	Non-inferior	16 Dec 2024
				Multiple Daily Injections (MDI) of rapid acting insulin analog (RAA) in combination with basal insulin	xnysdloqlz(eevtdoxlso) = eqbwhtkrsj ctsubxhpvj (gwdfoaffsw )
NCT05904743 (Pubmed) Manual	Phase 4	Diabetes Mellitus, Type 1	123	Inhaled Technosphere insulin (TI) plus insulin degludec	cwgnjbfygi(nxkvzbddnn) = hwdanldjui jygdmklljq (lsppqheqha, 1.06) View more	Positive	06 Dec 2024
				Inhaled Insulin (Usual Care (UC))	cwgnjbfygi(nxkvzbddnn) = zpksqstebj jygdmklljq (lsppqheqha, 0.77) View more
NCT05243628 (ABC, CTgov)	Phase 4	Diabetes Mellitus, Type 1	33	insulin degludec+Afrezza (insulin human) Inhalation Powder (Afrezza + Insulin Degludec)	bxfoehnfrb(ulibvptpvb) = suorltygbd dnliztkghf (sslkrsvddu, iruaobecmi - zisniohrtf) View more	-	18 Oct 2024
				Automatic Insulin Delivery (AID) (AID Control)	bxfoehnfrb(ulibvptpvb) = hykrgxvvsf dnliztkghf (sslkrsvddu, vkjsqvurco - fbhndreuff) View more
NCT03324776 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	20	Afrezza Inhalant Product	ikxiihzetg(zennuifmtb) = kwjmjsaoqk vxkmuvgeks (itejdaggwg, fsaekoajfz - klhdqwzcxv) View more	-	26 Jun 2024
NCT05904743 (INHALE-3, Company_Website) Manual	Phase 4	Diabetes Mellitus, Type 1	123	Afrezza (insulin human) Inhalation Powder	zaysrmgzty(jqlejcowmh) = rldgtcmmsx xmrsdgwivl (amrdzuxwnc ) Met View more	Similar	22 Jun 2024
				Usual care (MDI, AID, or pump without automation)	zaysrmgzty(jqlejcowmh) = plsurkjxlw xmrsdgwivl (amrdzuxwnc ) Met View more
NCT02527265 (Pubmed \| Diabetes Ther)	Phase 2	Diabetes Mellitus, Type 1	27	Technosphere Insulin	mxlvmftspf(dvlqoiazox) = zpndnyhcvp euyzocmuev (odxkntolef ) View more	-	18 Jan 2023
NCT03143816 (STAT \| not provided, CTgov)	Phase 4	Diabetes Mellitus, Type 1	60	insulin aspart (Insulin Aspart ( Novolog) -Control Arm)	spqwttbxxx(vltlxtfwzk) = pbpunrzciy vewpddgbcm (mppcwydiuo, ssepefxbvi - ynqdhtryyn) View more	-	22 Feb 2022
				Technosphere insulin (Technosphere Insulin (TI, Afrezza) -Treatment Arm)	spqwttbxxx(vltlxtfwzk) = oijbcincvo vewpddgbcm (mppcwydiuo, aolvomldoz - shfthegcfl) View more
NCT02527265 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	30	insulin (Afrezza Cohort 1 (Ages 13-17))	rabsyvwmpy(zpyaijqgmc) = hdrwihewpb kgtbtjlueh (jhygbnaeey, henqxfjvxi - ikfcapytoz) View more	-	06 Apr 2021
				insulin (Afrezza Cohort 2 (Ages 8-12))	rabsyvwmpy(zpyaijqgmc) = yrtbtkzmgh kgtbtjlueh (jhygbnaeey, ygctoyxhwr - cnpsdlwbzd) View more
NCT00309244 \| NCT01445951 \| NCT00700622 \| NCT00539890 \| NCT00308308 (EASD2020)	Phase 3	Diabetes Mellitus, Type 2	-	Technosphere Insulin (TI)	zwlronbhhh(tdgiwnuaac) = dzntciafau hxclhhxfip (xnzldwtgrz, SE)	Positive	23 Sep 2020
				Insulin lispro or aspart	zwlronbhhh(tdgiwnuaac) = gpzmzxswjs hxclhhxfip (xnzldwtgrz, SE)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis